IP Library › Granted Patent US 8,513,251
Granted Patent B2
US 8,513,251 · App. 13/543,296 · Granted Aug 20, 2013

Pyridazinone compounds

Inventors: Takahiko Taniguchi (Cambridge, GB); Jun Kunitomo (Kanagawa, JP)
Assignee: Takeda Pharmaceutical Company Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,513,251
App. No.
13/543,296
Granted
Aug 20, 2013
Kind
B2
Abstract

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I 0 ), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen atom, or a substituent; Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.

Claims (1)

1. 1-[4-(4-chloro-1H-pyrazol-1-yl)-2-fluorophenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, or a salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2026
From: TAKEDA PHARMACEUTICAL COMPANY LIMITED
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 075778/0924 →
Continuity (4)
Division 13148172
Provisional Application 61202207 · Feb 5, 2009
Provisional Application 61213927 · Jul 30, 2009
Related Publication 20120277430A1 · Nov 1, 2012